OGN Stock Summary and Trading Ideas (Organon & Co. Common | NYSE:OGN)

Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.

Organon & Co. Common trades on the NYSE stock market under the symbol OGN.

As of December 9, 2025, OGN stock price declined to $6.95 with 5,039,491 million shares trading.

OGN has a beta of 0.43, meaning it tends to be less sensitive to market movements. OGN has a correlation of 0.02 to the broad based SPY ETF.

OGN has a market cap of $1.81 billion. This is considered a Small Cap stock.

Last quarter Organon & Co. Common reported $2 billion in Revenue and $1.01 earnings per share. This beat revenue expectation by $29 million and exceeded earnings estimates by $.09.

In the last 3 years, OGN traded as high as $32.43 and as low as $6.18.

The top ETF exchange traded funds that OGN belongs to (by Net Assets): IJR, VTI, VB, VBR, VXF.

OGN has underperformed the market in the last year with a price return of -51.8% while the SPY ETF gained +13.6%. OGN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -33.4% and -1.6%, respectively, while the SPY returned +5.6% and +2.1%, respectively.

OGN support price is $7.07 and resistance is $7.51 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OGN shares will trade within this expected range on the day.